D-Wave Q2 2026 slides: bookings surge 1120% as revenue lags

D-Wave’s Q2 revenue fell to $3.1M, missing the $4.03M consensus by ~$0.96M (nearly -24%), and shares dropped 12.34% premarket to ~$18.75. Despite a 1,120% YoY surge in first-half bookings to $35.5M and 668% growth in remaining performance obligations to $40.7M, revenue conversion lagged the pipeline; liquidity declined to $546.2M from $819.3M after the $250M Quantum Circuits acquisition. Management guided for modestly higher Q3 revenue than Q2 and expected Q4 to rise sharply as most of the full-year revenue, with two annealing system deliveries in Q4 and some installation/cooling revenue carrying into 2027.

Analysis

The core issue is not demand, it is monetization velocity. In pre-revenue-ish infrastructure names, bookings can support multiple expansion only when there is a clear, repeatable path from pilot to installed base economics; here the market is being asked to capitalize a backlog that is still too small and too lumpy to underwrite durability. That makes the next 1-3 months about guidance credibility, not technology proof, and the first break in the story will likely be any delay in converting Q4 deliveries into revenue recognized on schedule.

Relative positioning matters: the market will likely continue rewarding the vendor with the most believable enterprise adoption curve and punishing the one that still looks like a science project with a sales pipeline. That argues for a quality spread favoring IBM over QBTS, while keeping an eye on IONQ/QUBT as sympathy names if investors decide today’s miss is evidence that the entire quantum basket is too early for institutional ownership. The second-order effect is tighter capital markets for the weaker names; once growth investors stop tolerating revenue misses, financing risk becomes a multiple issue before it becomes a solvency issue.

Contrarian view: the selloff may be partially overdone if the company’s Q4 revenue step-up is real and the booked systems actually ship without slippage. The bullish case is a short squeeze on any confirmation that install/calibration revenue can be recognized into 2027, but that requires evidence, not narrative. What would falsify the bearish thesis is a sharp sequential acceleration in recognized revenue and a raised near-term guide; absent that, this remains a ‘show me’ story with a high probability of another de-rating on any execution hiccup.

Key Decisions for Investors

• Short QBTS on strength after the initial post-update washout; 1-3 month horizon, looking for continued multiple compression unless management proves Q4 conversion. Stop if the stock reclaims the post-update gap and holds there for several sessions.
• Pair trade: long IBM / short QBTS for 1-3 months. IBM has a more credible enterprise monetization path, while QBTS is still trading on forward bookings rather than revenue quality. Risk: if QBTS posts a clean Q4 beat-and-raise, the spread can move against us quickly.
• Buy a small QBTS put spread into any rally if liquidity allows; structure around the next earnings/guidance window so the catalyst is data, not headline sentiment. Use defined risk because the name can squeeze on any backlog headline.
• Watch IONQ and QUBT as sympathy shorts only if the market starts treating the QBTS miss as an industry-wide commercialization warning. Do not initiate until correlation increases; otherwise idiosyncratic exposure is weak.
• If QBTS implies Q4 revenue materially above current run-rate, cover short exposure immediately; that would be the first credible sign that the bookings-to-revenue conversion problem is easing.